1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
D.Western Therapeutics Institute, Inc.

D.Western Therapeutics Institute, Inc.

TTSE:4576
65.00
JPY
-1.00
(-1.52%)
4.25BMarket Cap
Nov 12Next Earn
D.Western Therapeutics Institute, Inc.
TSE:4576
(Tokyo Stock Exchange)

Recent

price

65.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
JPY
- -
1.15
6.36
3.78
3.52
2.71
6.93
9.73
11.15
22.09
13.09
14.13
15.12
13.48
13.43
8.09
- -
Revenue per Share
-24.18
-20.46
-14.49
-10.49
-8.47
-12.99
-10.46
-59.89
-28.51
5.07
-10.16
-5.08
-14.5
-25.56
-36.74
-13.19
- -
Basic EPS, GAAP
-23.72
-19.9
-15.02
-9.52
-9.96
-14.25
-15.32
-30.7
-20.97
6.69
-8.15
-6.11
-12.3
-18.94
-37.28
-10.36
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
55.85
36.43
24.86
99.99
92.95
83.49
110.6
76.2
47.95
53.02
73.98
68.36
60.17
39.83
17.63
26.46
24.52
Book Value per Share
55.81
36.41
24.84
99.98
92.94
83.43
110.54
63.62
36.84
43.51
66.86
62.69
56.14
37.14
16.56
26.42
24.49
Tangible Book Value per Share
17
17
18
21
23
23
24
26
26
26
27
29
30
32
35
48
53
Basic Weighted Avg Shares
- -
20
113
80
80
62
168
254
293
581
356
414
448
428
472
388
- -
Sales/Revenue/Turnover
- -
-1,755.21
-229.06
-260.99
-246.12
-469.97
-190.3
-249.46
-268.44
20.21
-74.72
-41.42
-68.27
-186.42
-256.5
-159.92
- -
Operating Margin (%)
8
5
3
2
2
16
18
45
52
44
44
45
46
49
49
48
- -
Depreciation Expense
-418
-355
-256
-222
-193
-296
-254
-1,563
-749
133
-276
-149
-430
-812
-1,290
-632
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.46
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-1,773.33
-227.68
-277.71
-240.73
-479.59
-150.9
-615.48
-255.69
22.95
-77.65
-35.95
-95.89
-189.65
-273.61
-163.07
- -
Profit Margin (%)
946
622
438
2,255
2,089
1,998
2,741
2,359
1,496
1,527
2,293
1,969
2,448
1,944
1,343
1,816
1,710
Working Capital
- -
- -
- -
- -
- -
- -
- -
600
480
360
340
210
848
876
779
506
429
LT Debt
967
639
452
2,269
2,116
2,113
2,877
2,096
1,300
1,408
2,164
2,035
1,873
1,280
734
1,435
1,409
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
6.09
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
8.67
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-35.57
-44.2
-47.07
-16.33
-8.79
-14.7
-10.89
-65.98
-45.94
10.04
-15.52
-7.14
-22.24
-51.79
-128.16
-58.28
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
ST Debt
19
- -
154
LT Borrowings
1,090
- -
429
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
33
55
57
Market Capitalization
3,019
5,043
4,253

Working Capital

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
Total Current Assets
1,848
- -
1,898
Cash, Cash Equivalents & STI
1,301
- -
1,582
Accounts Receivable, Net
123
- -
96
Inventories
104
- -
128
Total Current Liabilities
96
- -
187
Payables & Accruals
- -
- -
- -
ST Debt
19
- -
154
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.04%
1.47%
95.6%
Free Cash Flow
-5.42%
40.99%
-62.07%
Net Income, GAAP
26.43%
47.85%
-51.01%
Sales/Revenue/Turnover
31.03%
2.51%
-17.8%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
105
119
- -
- -
472
2025
- -
- -
- -
- -
388
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-9.99
-6.02
- -
- -
-36.74
2025
- -
- -
- -
- -
-13.19
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
D. Western Therapeutics Institute, Inc. engages in the discovery and development of new biopharmaceuticals, primarily focusing on protein kinase inhibitors for ophthalmic, neuropathic, and respiratory conditions. The company offers Ripasudil hydrochloride hydrate (K-321) for Fuchs endothelial corneal dystrophy licensed to Kowa in the US and other regions; GLA-ALPHA (Ripasudil hydrochloride hydrate/Brimonidine tartrate) for glaucoma and ocular hypertension licensed to Kowa in Japan and Asia; DW-1002 and related products for ILM, ALC, ERM, and PVR membrane staining licensed to DORC in Europe, US, China, and other areas, and to Wakamoto Pharmaceutical in Japan; DW-1001 ophthalmic treatment agent licensed to ROHTO Pharmaceutical in Japan; H-1337 multi-kinase inhibitor for glaucoma and ocular hypertension under internal development in the US; DW-5LBT lidocaine patch for post-shingles neuropathic pain jointly developed with MEDRx in the US; and DWR-2206 regenerative medicine cell product for bullous keratopathy jointly developed with ActualEyes in Japan. Founded in 1999 and headquartered in Nagoya, Japan, with an R&D laboratory at Mie University, the company operates primarily in Japan while licensing products internationally to pharmaceutical partners and targets patients with eye diseases, pain disorders, and related conditions through alliances with universities and biotech firms; it maintains a consolidated subsidiary, Japan Innovative Therapeutics, Inc.. Recent developments include extension of its joint research agreement with the University of Fukui in May 2025 for novel cataract treatments; publication of favorable Phase IIb trial results for H-1337 glaucoma treatment in 2025 positioning it as a potential second-line option; commencement of Phase II trials in Japan for DWR-2206 regenerative cell therapy with ActualEyes; and ongoing Phase III preparations for K-321 while advancing multiple ophthalmic projects through strategic partnerships.